JIANGXI BIOLOGY(06915.HK) Launches Public Offering Today, Entry Fee Approximately HK$6,595.86
NewTimeSpace News: Jiangxi Institute of Biological Products Inc. (06915.HK) commences its public offering on 22 June, with a board lot of 500 shares and an entry fee of roughly HK$6,595.86. The offer price range is HK$9.33 to HK$13.06 per share. The Company plans a global offering of approximately 36.2345 million H-shares and expects to list on 30 June. WSH has been introduced as the sole cornerstone investor with a total subscription consideration of HK$50 million. Based on the median offer price of HK$11.20, it will subscribe for around 4.464 million Offer Shares, accounting for approximately 12.32% of the total Global Offering shares (assuming the Over-allotment Option is not exercised).
NewTimeSpace News: Jiangxi Institute of Biological Products Inc. (06915.HK, JIANGXI BIOLOGY) launches its public offering on 22 June 2026, with formal listing scheduled for 30 June 2026.
As disclosed in the prospectus, the total number of Offer Shares under the Global Offering is 36,234,500 H-shares, comprising 3,623,500 Hong Kong Offer Shares (subject to reallocation) and 32,611,000 International Offer Shares (subject to reallocation and the exercise of the Over-allotment Option). The offer price range stands at HK$9.33 to HK$13.06 per share. Each trading board lot contains 500 shares, translating to an entry fee of approximately HK$6,595.86 (calculated based on the maximum offer price). If the Over-allotment Option is fully exercised, a maximum additional 5,435,000 Offer Shares may be issued.
For cornerstone placement, the Company secured WSH as its only cornerstone investor with a total subscription amount of HK$50 million. Calculated at the median offer price of HK$11.20, WSH will subscribe for about 4,464,000 Offer Shares, representing approximately 12.32% of the total Global Offering shares (on the premise that the Over-allotment Option remains unexercised).
The Company is China’s largest manufacturer and exporter of tetanus antitoxin for human use. Measured by sales volume in 2024, it ranks first in both China and the global market, commanding a domestic market share of 65.8% and a global market share of 36.6%. It has maintained a domestic market share above 50% for 18 consecutive years.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Jiangxi Biology Passes HKEX Hearing, World’s Largest Provider of Human Tetanus Antitoxin
- Guotai CSI Coal ETF(515220) rises 1.56%, with a net inflow of 2.118 billion yuan over the past 14 trading days
- CSOP CSI 300 Index Daily (2x) Leveraged Product(07233.HK) Rises 0.18% in Morning Session at HK$5.580
- Fullgoal CSI Battery Thematic ETF(561160) rises 1.54%, with a total net inflow of 90.2232 million yuan for four consecutive days
- Invesco Qqq Trust(03455.HK) Rises 0.33% in Morning Session at HK$5,774.000
